These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17924065)

  • 1. [After the TGN1412 incident. Principles for assessment of first-in-man trials with monoclonal antibodies by the Paul Ehrlich Institute].
    Schneider CK; Kalinke U
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Oct; 50(10):1213-20. PubMed ID: 17924065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
    Stebbings R; Findlay L; Edwards C; Eastwood D; Bird C; North D; Mistry Y; Dilger P; Liefooghe E; Cludts I; Fox B; Tarrant G; Robinson J; Meager T; Dolman C; Thorpe SJ; Bristow A; Wadhwa M; Thorpe R; Poole S
    J Immunol; 2007 Sep; 179(5):3325-31. PubMed ID: 17709549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of phase I clinical trials with monoclonal antibodies in Germany--the regulatory requirements viewed in the aftermath of the TGN1412 disaster.
    Liedert B; Bassus S; Schneider CK; Kalinke U; Löwer J
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):1-9. PubMed ID: 17256444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.
    Hünig T
    FEBS J; 2016 Sep; 283(18):3325-34. PubMed ID: 27191544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. After TGN1412: recent developments in cytokine release assays.
    Stebbings R; Eastwood D; Poole S; Thorpe R
    J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
    Hünig T
    Nat Rev Immunol; 2012 Apr; 12(5):317-8. PubMed ID: 22487653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
    Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
    J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGN1412: scrutinizing preclinical trials of antibody-based medicines.
    Hansen S; Leslie RG
    Nature; 2006 May; 441(7091):282. PubMed ID: 16710395
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety of biologics, lessons learnt from TGN1412.
    Stebbings R; Poole S; Thorpe R
    Curr Opin Biotechnol; 2009 Dec; 20(6):673-7. PubMed ID: 19892543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primate testing of TGN1412: right target, wrong cell.
    Pallardy M; Hünig T
    Br J Pharmacol; 2010 Oct; 161(3):509-11. PubMed ID: 20880391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug trials in humans. Risks in the light of the London catastrophe].
    Otte A
    Internist (Berl); 2007 Jun; 48(6):636-41. PubMed ID: 17308913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Learning from the TGN1412 trial.
    Goodyear M
    BMJ; 2006 Mar; 332(7543):677-8. PubMed ID: 16554332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412.
    Dayan CM; Wraith DC
    Clin Exp Immunol; 2008 Feb; 151(2):231-4. PubMed ID: 18190459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The calm after the cytokine storm: lessons from the TGN1412 trial.
    St Clair EW
    J Clin Invest; 2008 Apr; 118(4):1344-7. PubMed ID: 18357347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies for use in man: current regulatory situation in the Federal Republic of Germany.
    Haase M
    Dev Biol Stand; 1990; 71():213-20. PubMed ID: 2205526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and side effects of monoclonal antibodies.
    Hansel TT; Kropshofer H; Singer T; Mitchell JA; George AJ
    Nat Rev Drug Discov; 2010 Apr; 9(4):325-38. PubMed ID: 20305665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies.
    Dhir V; Fort M; Mahmood A; Higbee R; Warren W; Narayanan P; Wittman V
    J Immunotoxicol; 2012; 9(1):34-42. PubMed ID: 22074378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?
    Tranter E; Peters G; Boyce M; Warrington S
    Br J Clin Pharmacol; 2013 Aug; 76(2):164-72. PubMed ID: 23438102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGN1412--a regulator's perspective.
    Schneider CK; Kalinke U; Löwer J
    Nat Biotechnol; 2006 May; 24(5):493-6. PubMed ID: 16680120
    [No Abstract]   [Full Text] [Related]  

  • 20. Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research.
    J Immunother; 1997 May; 20(3):214-43. PubMed ID: 9181460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.